IntroductionWe performed a single-arm meta-analysis to evaluate the efficacy and safety of JAK inhibitors in the treatment of dermatomyositis (DM)/ polymyositis (PM). MethodsRelevant studies from four
North America Janus Kinase (JAK) Inhibitors comes with extensive industry analysis of development components, patterns, flows, and sizes. The report calculates present and past market values to foreca
Ruxolitinib (rux) Phase II clinical trials are underway for the treatment of high-risk JAK2-rearranged (JAK2r) B-cell acute lymphoblastic leukemia (B-ALL). Treatment resistance to targeted inhibitors
Nail psoriasis is a manifestation of psoriasis localized to the nails, often presenting with pitting, onycholysis, and subungual hyperkeratosis. Currently, there are no FDA approved treatments specifi